Fibroadipogenic Progenitors (FAPs)

Mesenchymal-lineage stromal cells resident in the interstitium of skeletal muscle, defined by surface expression of PDGFRα with exclusion of endothelial (CD31+) and hematopoietic (CD45+) lineages. In mouse, Sca-1 positivity is an additional positive marker; in human, PDGFRα+/CD56⁻ (excluding satellite cells) is used. First identified concurrently by Joe et al. and Uezumi et al. in 2010 as a non-myogenic muscle-resident population capable of forming adipocytes and fibroblasts ¹². In healthy young muscle, FAPs are kept in check by regenerative signals and undergo TNF-α-driven apoptosis after their transient support role is complete ³ no-fulltext-access. With aging or chronic damage, FAPs fail to apoptose, accumulate in muscle, and differentiate into adipocytes (intramuscular fat) and activated fibroblasts (fibrosis) — directly contributing to sarcopenia and impaired regeneration ³ no-fulltext-access.

Identity and isolation

FAPs are operationally defined by immunophenotype and functional assays (adipogenic/fibrogenic differentiation in culture):

Marker	Mouse	Human	Notes
PDGFRα (CD140a)	+	+	Canonical FAP marker; PDGF receptor alpha
Sca-1 (Ly6A)	+	—	Used in mouse only; no direct human equivalent
CD31 (PECAM-1)	−	−	Endothelial exclusion
CD45	−	−	Hematopoietic exclusion
SM/C-2.6	−	—	Mouse satellite-cell exclusion marker used by Uezumi 2010; no direct human equivalent in this paper
Lin (B220, CD3, Ter119 + other)	−	—	Mouse lineage exclusion cocktail (Joe 2010 strategy)

Joe 2010 isolated FAPs as the Hoechst^mid/PI⁻/CD45⁻/CD31⁻/Sca-1⁺/CD34⁻ fraction (the Sca-1⁺CD34⁻ gate within the Lin-dump population), with PDGFRα used for in-situ validation and confirmation that >85% of FAPs are PDGFRα+ ¹. The Uezumi group used PDGFRα as the primary positive selection marker, gating on CD31⁻/CD45⁻/SM/C-2.6⁻/PDGFRα⁺ in mouse ². Both strategies converge on the same interstitial PDGFRα⁺ population. In human muscle, Uezumi 2010 used PDGFRα+/CD56- gating to enrich FAPs from the mononuclear cell fraction ².

Note: Cell Ontology lacks a dedicated term for the mouse FAP phenotype as of 2026-05. CL:0002320 (connective tissue cell) encompasses FAPs but is too broad for precise querying. A dedicated FAP CL term has been proposed but not finalized. needs-canonical-id

Multipotent lineage output

FAPs are multipotent but not pluripotent. In culture:

Adipocytes: readily induced by adipogenic cocktail (insulin/dexamethasone/rosiglitazone); the canonical FAP lineage output associated with pathology ²
Fibroblasts / myofibroblasts: induced by TGF-β1 stimulation; produce collagen I, fibronectin — the fibrogenic arm ³ no-fulltext-access — fibrogenic differentiation claim attributed to Lemos 2015 (not_oa); TGF-β1-driven fibrogenesis is broadly accepted in the literature but unverified against this specific PDF
Chondrocytes: reported in vitro; physiological relevance in muscle is unclear no-mechanism
Osteoblasts: reported in some protocols; contested as an artifact of culture conditions contradictory-evidence

FAPs do not give rise to myocytes under standard conditions. They are Pax7-negative and MyoD-negative, distinguishing them definitively from satellite-cells (Pax7+, MyoD+/−). PDGFRα+ FAPs that acquire myogenic markers have been described rarely and are considered exceptional, not constitutive ¹.

Homeostatic role in regeneration

In healthy muscle, FAPs are pro-regenerative. After acute injury (cardiotoxin, glycerol, laceration), FAPs transiently expand in the first 2–4 days, releasing paracrine signals that support satellite-cell activation and myoblast differentiation. Key mechanisms:

Eosinophil-FAP-myogenesis axis (IL-4 signaling)

Heredia et al. 2013 showed that in the regenerating muscle milieu, type 2 innate immune signals drive FAP pro-myogenic behavior ⁴. Eosinophils (identified as CD11b⁺/Siglec F⁺ cells in the 4get IL-4-reporter mouse) are the dominant IL-4-secreting cell type in injured muscle, appearing within 1–2 days post-injury. IL-4 acts directly on FAPs (via IL-4Rα/STAT6) to suppress their adipogenic program (repressing PPARγ, Lep, Fabp4, Acaca, Cd36, Dgat2) and promote secretion of paracrine factors (including myogenic gene-inducing mediators) that stimulate myogenesis. IL-4 also promotes FAP proliferation (~2-fold at 48 h, ~4-fold at 72 h) and necrotic debris clearance by FAPs. In eosinophil-deficient ΔdblGATA mice (GATA-1 high-affinity site deletion, which ablates the eosinophil lineage), muscle regeneration is severely impaired and intramuscular fat deposition increases — a deficit partially rescued by IL-4 complex injection (n = 6 per treatment). This established FAPs as signal-integrating cells whose fate (myogenesis-support vs. adipogenesis) is controlled by the immunological context of the muscle environment.

Dimension	Status
Pathway conserved in humans?	partial
Phenotype conserved in humans?	unknown
Replicated in humans?	no

FAP support of satellite-cell niche

Wosczyna et al. (2019) demonstrated that FAP depletion impairs both skeletal muscle regeneration and long-term homeostatic maintenance ⁵. Using a PDGFRα^CreER;R26^DTA knockin system (Cre-dependent diphtheria toxin A expression, achieving ~75% FAP depletion following tamoxifen; n=5–9 per group), they showed: (1) after CTX injury, FAP-depleted mice had impaired MuSC and HC expansion, smaller regenerating myofibers at 14 dpi (mean myofiber CSA significantly reduced), and a significant regenerative deficit rescued by transplantation of donor GFP+ FAPs; and (2) under uninjured homeostatic conditions over 9 months, FAP-depleted mice exhibited reduced lean mass (significant from 3 months), reduced forelimb and hindlimb force, muscle fiber atrophy (smaller myofiber CSA at 9 months), and an approximately 45% reduction in MuSC numbers (n=4–6). Local TA-targeted FAP depletion via endoxifen-PCL implant recapitulated the atrophy phenotype without systemic effects, confirming that local muscle-resident FAPs are the relevant population. This establishes that FAPs are required for long-term homeostatic maintenance of both skeletal muscle fiber size and the MuSC pool — not just for acute regeneration.

Dimension	Status
Pathway conserved in humans?	unknown
Phenotype conserved in humans?	unknown
Replicated in humans?	no

needs-human-replication — FAP homeostatic niche requirement demonstrated only in mouse (PDGFRα^CreER;R26^DTA model); human muscle biopsy studies have not isolated the causal niche interaction between FAPs and MuSCs.

TNF-α apoptosis gate: the regeneration/fibrosis switch

The central mechanism distinguishing successful regeneration from fibrosis is the fate of FAPs after they perform their niche role. Lemos et al. 2015 described this in molecular detail ³:

Acute injury milieu: High TNF-α (from infiltrating macrophages and neutrophils) drives FAP apoptosis via TNFR1 → caspase-8 pathway. FAPs expand transiently, support satellite cells, then die — leaving a clean regenerative field. no-fulltext-access — Lemos 2015 is closed-access; this mechanistic detail is consistent with the known TNF-α/TNFR1 pathway biology but has not been verified against the full PDF.
Chronic damage milieu (dystrophic muscle, repeated injury): TNF-α levels are persistently elevated but FAPs acquire resistance to TNF-α-induced apoptosis. FAPs survive, persist, and differentiate into adipocytes/fibroblasts → fatty infiltration and fibrosis.
Nilotinib (BCR-Abl/PDGFR kinase inhibitor) restores FAP apoptosis sensitivity in dystrophic mice (mdx model), reducing fibrosis — establishing this apoptosis mechanism as druggable. no-fulltext-access — nilotinib mdx result unverified against PDF.

This switch between apoptosis sensitivity and resistance is the proximate mechanism linking the immune/inflammatory context to the FAP contribution to pathology. The molecular details of apoptosis resistance acquisition in chronic damage are not fully resolved. no-mechanism

Dimension	Status
Pathway conserved in humans?	partial
Phenotype conserved in humans?	yes (fatty infiltration in muscular dystrophy and aging)
Replicated in humans?	no (mechanistic; observational replicated)

Aging biology: dysregulated FAPs drive sarcopenic pathology

With aging, FAPs become dysregulated in several ways that collectively drive sarcopenia:

1. Failure to apoptose after injury

Aged muscle shows impaired clearance of FAPs post-injury, resembling the chronic-damage milieu in young dystrophic mice ³. The mechanism likely involves reduced TNF-α sensitivity and altered macrophage polarization in aged muscle (shift toward M2-like anti-inflammatory macrophages that produce less TNF-α acutely). The result is FAP accumulation and inappropriate differentiation. needs-replication — aging-specific FAP apoptosis kinetics not directly measured in aged wild-type mice in Lemos 2015; extrapolated from chronic damage model.

2. Adipogenic shift via WNT5a/GSK3/β-catenin dysregulation

Aged and dystrophic FAPs show increased adipogenic differentiation potential driven by altered WNT signaling ⁶. FAPs from dystrophic (mdx) mice have reduced WNT5a expression (confirmed in two independent bulk RNAseq datasets), reduced active (non-phosphorylated) β-catenin, and increased active GSK3 (reduced pGSK3 Ser9) compared to wild-type FAPs. GSK3 phosphorylates β-catenin targeting it for proteasomal degradation, releasing transcriptional repression of PPARγ and driving adipogenesis. Key quantitative findings:

Exogenous WNT5a (200 ng/ml) reverses FAP adipogenesis by phosphorylating GSK3 Ser9 → β-catenin stabilization → PPARγ suppression
GSK3 inhibition by LY2090314 fully abrogates FAP adipogenesis ex vivo (IC50 = 6.57 nM in mdx FAPs) and reduces intramuscular fat in glycerol-injured mice in vivo (25 mg/kg IP × 3 days; n = 3–4)
Old mdx FAPs (18-month-old) show further increases in adipogenic gene expression (C/ebpa, Pparg1) and reduced pro-myogenic factor production (Igf1, Il6) compared to young mdx FAPs (1.5-month-old)
Single-cell mass cytometry (CyTOF) reveals β-catenin downregulation marks FAPs committed to adipogenesis

This identifies the WNT5a → GSK3 → β-catenin → PPARγ axis as the central regulator of FAP adipogenic fate. Note: Reggio 2020 does NOT characterize senescent FAPs by p16^INK4a, p21, or SA-β-galactosidase, and does NOT test ABT-263/navitoclax — those claims were incorrectly attributed in the initial extraction. needs-human-replication — WNT5a/GSK3 axis validated in mouse mdx and glycerol-injury models; not tested in human aged muscle.

4. Impaired support of satellite cells

Aged FAPs are less effective niche supporters for satellite-cells. Reggio 2020 shows that old mdx FAPs (18-month) produce lower Igf1 and Il6 — key pro-myogenic signals — and have increased adipogenic gene expression compared to young mdx FAPs, consistent with a secretome shift away from myogenic support ⁶. Whether this reflects quantitative (fewer FAPs) or qualitative (altered secretome composition) differences in aged wild-type muscle is not fully established. Given the homeostatic dependence of satellite cells on FAPs demonstrated in young mice ⁵, FAP aging likely contributes to satellite cell functional decline underlying stem-cell-exhaustion. no-mechanism — cell-autonomous vs. niche-driven basis of aged FAP dysfunction not resolved.

Hallmark connections

Hallmark	Mechanism
stem-cell-exhaustion	FAP depletion causes ~45% MuSC decline over 9 months; aged FAPs are less effective niche supporters ⁵
chronic-inflammation	FAP survival in pro-inflammatory chronic damage milieu; TNF-α apoptosis resistance ³ no-fulltext-access
cellular-senescence	Senescent FAP subpopulations have been proposed in aging/dystrophic muscle, but Reggio 2020 characterizes WNT/β-catenin dysregulation rather than canonical senescence markers; dedicated senescent-FAP characterization in aged wild-type muscle is an open gap needs-replication

Therapeutic implications

FAP-targeting strategies relevant to aging-related muscle pathology:

GSK3 inhibition — LY2090314 abrogates FAP adipogenesis (IC50 6.57 nM in mdx FAPs) and reduces glycerol-induced intramuscular fat in vivo ⁶; no clinical program in muscle disease; GSK3 inhibitors have CNS and oncology programs but not aging muscle needs-human-replication
WNT5a restoration — exogenous WNT5a (200 ng/ml) suppresses FAP adipogenesis ex vivo via GSK3/β-catenin ⁶; no clinical program identified long-term-unknown
PDGFR inhibition — nilotinib claimed to restore FAP apoptosis in mdx mice ³ no-fulltext-access; clinical trials in muscle disease are limited; off-target cardiac toxicity is a concern
IL-4/type 2 immune augmentation — eosinophil-derived IL-4 acts on FAPs to suppress adipogenesis and promote myogenesis ⁴; IL-4 complex injection rescued muscle regeneration deficits in ΔdblGATA mice in vivo; no clinical program in aging muscle
Senolytics targeting senescent FAPs — ABT-263/navitoclax has been discussed in the FAP context but was NOT tested in Reggio 2020; this claim requires a different or future citation needs-replication needs-human-replication

None of these strategies has been tested in human aging-related sarcopenia specifically. All remain preclinical. needs-human-replication

Limitations and gaps

#gap/needs-canonical-id — No dedicated Cell Ontology term for FAPs as of 2026-05; cell-ontology-id field left null.
#gap/needs-human-replication — Core FAP biology (apoptosis switch, satellite-cell niche dependence, aging changes in adipogenic potential, WNT5a/GSK3 axis) established primarily in mouse (C57BL/6, mdx). Heredia 2013 used male BALB/cJ and C57BL/6 background mice aged 8–16 weeks; Wosczyna 2019 used C57BL/6 PDGFRα^CreER mice; Reggio 2020 used C57BL/6J (wt) and C57BL/10ScSn-Dmd^mdx/J mice with sexes balanced. Human FAP characterization exists (Uezumi 2010 human biopsy data) but mechanistic claims are mouse-only.
#gap/needs-replication — Senescent-FAP characterization in aged wild-type muscle (p16+/p21+/SA-β-gal+) requires a dedicated study; Reggio 2020 addresses WNT/β-catenin dysregulation rather than senescence per se. ABT-263/navitoclax in FAP context is uncited here.
#gap/no-fulltext-access — Lemos 2015 (doi:10.1038/nm.3869, not_oa): TNF-α/TNFR1/caspase-8 apoptosis-switch mechanism and nilotinib mdx result unverified against full PDF.
#gap/no-mechanism — Molecular basis of FAP apoptosis resistance in chronic damage and aging is incompletely defined; chondrogenic and osteogenic lineage output under physiological conditions unclear.
#gap/needs-singlecell-data — Single-cell transcriptomic aging signature of FAPs not integrated; Tabula Muris Senis and CellxGene Census contain FAP-enriched clusters under interstitial/stromal annotations (Reggio 2020 uses Tabula Muris Consortium and Giordani et al. datasets to characterize FAP WNT ligand expression but does not report an aging signature); cross-check needed.
#gap/long-term-unknown — Long-term consequences of therapeutic FAP clearance on muscle structure and regenerative reserve are not characterized; Wosczyna 2019 shows FAPs are required for homeostasis, so ablation strategies carry risk.

Footnotes

joe-2010-fap-identification · in-vivo + in-vitro · n=6 per group (transplantation experiments) · model: mouse (C57BL/6 + ROSA26-GFP + Myf5-Cre-R26R3-YFP) + human muscle biopsy · doi:10.1038/ncb2015 · locally downloaded; PDF verified 2026-05-06 ↩ ↩² ↩³
uezumi-2010-fap-ectopic-fat · in-vivo + in-vitro · n=6 per group (transplantation experiments) · model: mouse (C57BL/6) + human muscle biopsy · doi:10.1038/ncb2014 · locally downloaded; PDF verified 2026-05-06 ↩ ↩² ↩³ ↩⁴
lemos-2015-tnf-fap-apoptosis-fibrosis · in-vivo · model: mdx mouse + C57BL/6 · doi:10.1038/nm.3869 · not_oa per archive no-fulltext-access — TNF-α apoptosis switch mechanism (TNFR1/caspase-8) and nilotinib mdx result unverified against full PDF ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸
heredia-2013-il4-eosinophil-fap-myogenesis · in-vivo + in-vitro · n=4–6 per genotype · model: mouse (BALB/cJ and C57BL/6 background; eosinophil-deficient ΔdblGATA; IL-4Rα-null Il4rα⁻/⁻; Il4/Il13⁻/⁻; myeloid-specific Il4rα^fl/fl LysM^Cre; PDGFRα-Cre conditional Il4rα deletion) · doi:10.1016/j.cell.2013.02.053 · locally downloaded; PDF verified 2026-05-06 ↩ ↩²
wosczyna-2019-fap-satellite-cell-niche · in-vivo · n=3–9 per group · model: mouse (C57BL/6; PDGFRα^CreER;R26^DTA for FAP ablation; PDGFRα^CreER;R26^NG for GFP-labeling) · doi:10.1016/j.celrep.2019.04.074 · Note: the DOI previously cited as 10.1016/j.celrep.2019.07.073 is incorrect — that DOI resolves to a VISTA protein paper; correct DOI confirmed via PubMed (PMID:31091443); PDF downloaded fresh and verified 2026-05-06 ↩ ↩² ↩³
reggio-2020-wnt-gsk3-fap-adipogenesis · in-vivo + in-vitro · n=3–4 per group · model: mouse (C57BL/6J wt; C57BL/10ScSn-Dmd^mdx/J; sexes balanced; young 45-day-old and old 18-month-old mdx) + single-cell mass cytometry (CyTOF) of mdx FAPs · doi:10.1038/s41418-020-0551-y · locally downloaded; PDF verified 2026-05-06. Topic: WNT5a/GSK3/β-catenin regulation of FAP adipogenesis — this paper does NOT characterize senescent FAPs by p16/p21/SA-β-gal markers and does NOT test ABT-263/navitoclax ↩ ↩² ↩³ ↩⁴

🧬 Aging Wiki

Explorer

fibroadipogenic-progenitors